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Abstract  Liver  diseases  are  a  major  health  problem  worldwide,  making  it  necessary  to  develop
new molecules  that  help  counteract  or  prevent  such  diseases.  On  account  of  this fact,  inves-
tigations aiming  to  obtain  natural  and/or  synthetic  compounds  possessing  hepatoprotective
activity have been  undertaken.  The  development  of  new  drugs  consists  of a  variety  of steps,
ranging from  the  discovery  of  the  pharmacological  effects  in cellular  and  animal  models,  to
finally demonstrate  their  efficacy  and safety  in  humans.  Different  models  for  assessment  of
the hepatoprotective  activity  in  vitro, ex  vivo  and  in vivo can  be found  in medical  literature.
The purpose  of this  review  is  to  show  the  features,  main  advantages  and disadvantages  of  each
of the  models,  the  hepatotoxic  agents  most  commonly  used  (CCl4,  acetaminophen,  ethanol,  d-
galactosamine,  t-BuOOH,  thioacetamide)  as  well  as  the  biochemical  parameters  useful  to  assess
liver damage  in  the  different  models.
©  2016  Universidad  Auto´noma de Nuevo  Leo´n.  Published  by  Masson  Doyma  Me´xico  S.A. This  is
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Introduction
The liver  is  a  key  organ.  It regulates  different  functions
in the  body,  such  as  metabolism,  secretion,  storage  and
detoxifying.  Liver  damage  is  usually  associated  with  the dis-
tortion  of  some  of  these  functions.  The  liver  is  continuously
exposed  to  an elevated  amount  of  toxic  agents,  because
the  portal  vein  supplies  blood  to  this  organ  after  intestinal
absorption.1,2
The  World  Health  Organization  (WHO)  determined  that
around  2.4  million  deaths  yearly  are linked to  some  liver
disease,  and  that  around  800  thousand  of  these  deaths  are
attributable  to  cirrhosis.3 On the other  hand,  epidemiologi-
cal  studies  conducted  by  the National  Institute  of  Statistics
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Figure  1  Mechanism  of  liver  damage  due  to  oxidative  stress.
and Geography  (INEGI  by  its  Spanish  acronym)  indicate
that  in  2013  in Mexico,  over  600  thousand  deaths  were
recorded.  The  main  causes  were  diabetes  mellitus  (14.25%),
followed  by  ischemic  heart  diseases  (12.63%),  cerebrovascu-
lar  diseases  (5.29%)  and  liver  diseases  (4.79%).  Despite  the
advances  in  modern  medicine  and  the  development  of  new
hepatoprotective  drugs,4--6 the  incidence  of  hepatic  diseases
has  not  decreased  or  stopped;  on  the  contrary,  statistics
suggest  that  these  continue  to  increase.7,8
Metabolism  or  biotransformation  of  hepatotoxic  agents
is  a  detoxifying  process  where  molecules  are  surgically
modified  into  less  toxic  shapes  by  different  enzymatic  sys-
tems.  These  modifications  can  generate  metabolic  products
with  varying  degrees  of pharmacological  activity  or  inactive
metabolites.  There  are  different  types  of  metabolic  reac-
tions:  phase  1 reactions  are usually  oxidations,  reductions  or
hydrolysis  (modifying  the structure  of  the  reactive  group);
phase  2 reactions  are  those  in  which  the drug conjugates
with  glucuronic  acid,  sulfates,  acetates,  methyl  groups,  glu-
tathione  or  amino  acids,  generally  to  increase  its  solubility
and  be  excreted.  The  liver’s  ability  to  be  able to  carry  out
the  different  oxidative  metabolisms  is  associated  with  the
high  cytochrome  P450  cell  content.9
Due  to  the  high  metabolite  biotransformation  rate,  free
radicals  can  be  generated  continuously.  Most  hepatotoxic
substances,  mainly  damage  the  liver  because  of  the gen-
erated  oxidative  stress;  oxygen  reactive  species  induced  a
rise  in  lipid  peroxidation,  a  reduction  of  ATP  and oxidative
damage  in  the  DNA and  proteins  (Fig.  1).10--13
Protecting  the  liver  from  the  harmful  effects  of
hepatotoxins-  which may  be  ingested-  or  counteracting  the
alterations  in the  antirradical  defense  mechanisms,  is  very
important;  the agents  capable  of  doing  this are called
hepatoprotective.14
For  this  reason,  researches  have  been  developed
in  the  search  of  natural  and/or  synthetic  compounds
with  hepatoprotective  activity.8 The  development  of  new
pharmaceuticals  consists  of a  variety  of  steps,  going  from
the  discovery  of  pharmacological  side  effects  in cellular  and
animal  models,  to  finally  prove  its  efficacy  and  safety  in
human  beings.1
In vivo  and  well  as  ex vivo  test  models  are  used  to
evaluate  hepatoprotective  activity.  These  systems  mea-
sure  the  ability  of  the  drug  to  prevent  or  cure  hepatic
toxicity  (induced  by  different  hepatotoxins)  in cellular  cul-
tures,  organs  or  in  experimental  animals  (rats,  mice,  etc.)
respectively.1
Evaluation  models
Nearly  every  acute  and chronic  liver  injury  can  be exper-
imentally  induced;  necrosis,  steatosis,  hepatic  injuries,
cirrhosis  and  cholestasis.  These  can  all  be generated  in  dif-
ferent  models  of liver  damage.
The  objective  of  hepatoprotective  models  is  for  the  com-
pounds,  fractions  or  extracts  being  tested  to counteract
or  avoid  the damage  generated  by  hepatotoxins.  The  mag-
nitude  of  the  hepatoprotective  effect  can be measured
through  biochemical  makers,  survival  rate  or  histology  of
the  liver.
Test methods  may  be in vitro,  ex vivo  or  in  vivo  (Table  1);
and  each one  of them can  be evaluated  to  see  if the  sub-
stance  is  hepatoprotective  or  hepatocurative,  depending  on
if  the  hepatoprotective  agent  is administered  before  or  after
the  hepatotoxin.
In vitro  models
Fresh  hepatocytes,  primary  hepatocyte  cultures  and immor-
talized  cell lines  are  used  to  measure  the hepatoprotective
effect.  It is  possible  to establish  action  mechanisms  in  these
models.  These  models  represent  the  best option  for  the
screening  and  selection  of  potential  hepatoprotective  com-
pounds  and  it is  possible  to  establish  action  mechanisms  at
a  cellular  and  molecular  level.15,16
Primary  hepatocyte  cultures  have  the  characteristic  of
maintaining  normal metabolic  liver  properties,  but  it is  not
possible  to  maintain  them  for a long  time.  On the  other  hand,
cell  lines  maintain  their  properties  stable  for  a long  time
and  can  be cryopreserved,  but  immortalized  or  carcinogenic
lines  may  differ  in  biochemical  and  metabolic  aspects  from
normal  cells.1
In order  to evaluate  protection,  parameters  like
transaminase  liberation,  cell  multiplication,  morphology,
macromolecular  synthesis,  oxygen  consumption,  etc.,  are
measured.17,18
Advantages  of  in vitro models  are:  They are quick  tests
(between  2--3  testing  days),  they  require  small amounts  of
the  test  substances  (milligram  range)  and  the experimen-
tal conditions  may  be strictly  controlled;  different  samples
may  be analyzed  in the  same  test,  they  are cheap  tests  and
there  is  little  variability;  therefore  they  are  considered  a
reproducible  test. In  the case  of  primary  cultures  or  fresh
hepatocytes,  they  require  few  experimental  animals  in com-
parison  to  in  vivo  models.
Disadvantages  of  in  vitro  models:  cells  do not  function
independently  in the  organism;  on  the contrary,  they  form
close  and  complicated  nets  with  each other  and  with  the
extracellular  matrix;  therefore,  this  should  be taken  into
consideration  when  interpreting  in vitro data  and should
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Table  1  Models  of  evaluations  of  hepatoprotective  activity.
Model  Examples  Advantages  Disadvatages
In  vitro  *  Fresh  hepatocytes
* Primary  hepatocyte
culture
* Immortalized  cell  lines
(HepG2,  HUH7,  HepRG)
*  Quick  and  cheap  tests
* Requires  few  samples
*  High  control  of
variables;  reproducible
* Can  analyses  various
samples  in  the  same  test
*  Due  to  a  lack  of  complexity  present
in the  organ  of  biological  system,
results  should  be interpreted  with
caution.
* Samples  do not  undergo  any
biotransformation  process
Ex vivo  *  Precise  liver  cuts
* Isolated  perfused  liver
*  Resemble  the in vivo
environment
* Decrease  the  number
of  animals  experimented
on
*  A human  tissue  model
can  be developed
*  Low  oxygenation  rate  in the
internal  cells
*  Low  cut  viability  (1--10  días)
*  There  are  significant  differences  in
size  and  fuction  between  human  and
murine  tissue.
In vivo  *  Murine  model  *  Widely  used
*  There  is a greater
correlation  with  what
happens  in humans
* All  biochemical  and
histological  parameters
can  be measured
*  Requires  a  large  number  of  animals
to  experiment  on
*  Interindividual  variation  exists
* A larger  simple  size  is required
*  Large  and  expensive  experiments
be  verified  with  in  vivo  systems.  Isolated  cells  as  well  as
cell  lines  have  an elevated  cell differentiation  rate  due  to
the  loss  of  natural  environment.  The  substances  tested  do
not  go  through  the absorption  and distribution  processes,
which  occurs  in  the  organism.  There  is  little  to  no  cell-to-
cell  interaction  and  there  is  no  complexity  proper of  the
organ.19--21
Ex  vivo  models
Precision  cut  liver  slices  (PCLS)  are  an ex  vivo  tissue  culture
which  imitates  multicellular  characteristics  of  in vivo
organs.  Cellular  interaction  and  spatial  disposition  remain
intact  in  this  model,  with  the possibility  of  performing  mor-
phological  studies.  Liver  slices  have the characteristic  of
functionally  maintaining  metabolizing  enzymes  and  biliary
canaliculus21;  they  have  proven  to  be  a valid  ex vivo  sys-
tem  to study  metabolism  and  liver  damage  and function  as
a  bridge  between  in  vivo  systems  and cell  cultures.22
Isolated  perfused  livers  represent  a  model  combining
in  vitro  characteristics  under  in  vivo  circumstances.  The
first  model  was  developed  in porcine  livers  and  later  the  liv-
ers  of  smaller  animals  (rats,  mice  and  rabbits).  This  model
preserves  the  tridimensional  structure  as  well  as  the cell-to-
cell  interactions  with  the  possibility  of  collecting  bile  in real
time.  If  blood  is  used as  a perfusor  liquid,  then  hemodynamic
parameters  may  be  studied.23
Advantages  of  ex  vivo  models:  they  resemble  in  vivo
atmospheres,  are  low cost, reproducible  models.  In  PCLS  the
number  of experimental  animals  is  reduced,  also  the  model
can  be developed  with  human  organs.
Disadvantages  of  ex vivo  models:  in  PCLS  the  bile  flow
and  functional  parameters,  such as  portal  flow,  cannot  be
analyzed.1 There  is  poor  diffusion  of  oxygen  nutrients  to
the  more  internal  cells,  and  even  with  the development  of
new  means  of  culture,  the viability  of  the  slices  remains
short  (8--10  Days).22 In small  labs,  because  of  space  and
budget,  the best  option  is  the  development  of  perfused  rat
liver;  however,  there  are  significant  differences  in  the  size,
function  and  geometry  of  the murine  liver  compared  to  the
human.1
In vivo  model
This model  has  been  widely  used;  through  this model  we
are  able  to  determine  the protection  mechanism.  The  dam-
age  produced  in experimental  animals  due to  known  dosage
administration  of  different  hepatotoxins  and  the  magni-
tude  of  the  damage and/or  protection  is  determined  by
the  different  biochemical  and  metabolic  markers,  as  well
as  histopathological  determinations.
Advantages  of  in  vivo  models:  is  the model  with  the high-
est  degree  of correlation  with  what  occurs  in  humans  and  all
biochemical  and  histopathological  parameters  can  be  mea-
sured.  They  let us take  into  account  the  possible  effects of
the  immune  and central  nervous  systems  in  the development
of  hepatic  diseases.24
Disadvantages  of  in  vivo  models:  they  require  a  large
number  of  animals,  and usually  the studies  are  developed
for  long  periods  of  time,  increasing  ethical  and  financial
aspects.  There  is  an inter-individual  variation,  and  even
though  models  imitating  the different  hepatic  diseases
have  been  developed,  there  are relevant  differences  in
the molecular  pathogenesis  between  the  model  and  human
species.  They  require  a  larger  sample  size  to  perform  the
experiment  which  may  be  a  limiting  factor,  especially  when
analyzing  natural  products.25
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Hepatotoxic  agents  and  their  action
mechanisms
The  molecules  responsible  for liver  damage  are called  hep-
atotoxins;  nowadays  it is  possible  to  imitate  any  form  of
natural-origin  hepatic  disease  with  different  chemical  sub-
stances  and  pharmaceuticals.
Hepatotoxins  may  be  classified  as  intrinsic  if the  agent’s
behavior  is  predictable;  there  is  a period  of  constant
latency  between  exposure  and  liver  damage  development,
or  the  injury  is  dose-dependent  (i.e.  carbon  tetrachloride
{CCl4},  thioacetamide,  acetaminophen,  ethanol).  Another
classification  is  idiosyncratic,  if the agents  are not pre-
dictable,  but  generate  liver  damage  in just a  small  portion
of  exposed  individuals,  the injury  is  not  related  to  the
dosage,  it  occurs  after a  variable  latent  period  and  it is
not  reproducible  in experimental  animals  (i.e.  halothane,
sulfonamides,  isoniazid).26,27
Carbon  tetrachloride  (CCl4)
CCl4 toxicity  depends  on  dosage  and  the duration  of expo-
sure.  In low  dose, effects  like  loss  of  Ca2+ homeostasis,  lipid
peroxidation,  and release  of  cytokines  are  produced,  and
apoptotic  events  may  be  generated,  followed  by cellular
regeneration.  In high  doses,  or  if  there  is  a longer  exposure,
the  effects  are  more  severe  and  the damage  occurs  during
a  longer  period  of  time,  the patient  may  develop  fibrosis,
cirrhosis,  or  even  cancer.5,28,29
CCl4 is  metabolized  by  the cytochrome  P450 dependent  of
monooxygenases,  mainly  through  the CYP2E1  isoform  in  the
endoplasmic  reticulum  and  mitochondria.16 Hepatotoxicity
is  produced  by  the formation  of  the trichloromethyl  radical
(CCl3), which  is  highly  reactive.  These  radicals  may  satu-
rate  the  organism’s  antioxidant  defense  system,  react  with
proteins,  attack  unsaturated  fatty  acids,  generating  lipid
peroxidation,  reduce  the  amount  of  cytochrome  P450,  which
leads  to  a  functional  failure  with  the consequent  lowering  of
protein  and  accumulation  of  triglycerides  (fatty  liver), and
alter  water  and electrolyte  equilibrium  with  an increase  of
hepatic  enzymes  in  plasma.30
Lipid  peroxidation  leads  to  a cascade  of  reactions,  such
as  the  destruction  of  membrane  lipids,  the generation  of
endogenous  toxic  substances,  which  originate  more  hepatic
complications  and  functional  anomalies.  For  this  reason,
lipid  peroxidation  is considered  a  critical  factor  in the patho-
genesis  of  liver  injuries  induced  by  CCl4.
15 The  inhibition  of
the  radical  CCl3 generation  is a  key point  in the protec-
tion  against  the  damage  generated.  Because  of  this,  this
model  is widely  used for  the evaluation  of  pharmaceuticals
and  natural  products  with  hepatoprotective  and  antioxidant
activity.31,32
Acetaminophen
It  is  an  analgesic  antipyretic  analgesic.  In high  doses,  it
produces  acute  liver  damage,  causing  necrosis  of  the  hepa-
tocytes.  It is a widely  used  experimental  model  of  clinical
importance  as  an example  of  drug-induced  liver  damage.16
At  therapeutic  doses,  it is  mainly  metabolized  to  glu-
curonic  or  sulfated  and  excreted  derivatives,  the  rest
metabolizes  to  intermediate  reactives,  which  are  elimi-
nated  by  conjugation  with  glutathione.  At  overdoses,  the
excess  is  oxidized  by the  cytochrome  P450  (mainly  the
CYP2E1  isoform)33 at N-acetyl-p-benzoquinone  (NAPQI),
which  quickly  attaches  to  glutathione.  Under  excessive  con-
ditions  of  NAPQI  and  glutathione  depletion,  a covalent  bond
of metabolite  to  proteins,  adduct  formation,  mitochondrial
dysfunction  and  oxidative  stress  occurs.  The  result  is necro-
sis  or  hepatocellular  death.19,34
Ethanol
The  liver  is  the  most  susceptible  organ  to  the  toxic  effects  of
ethanol.  The  damage  mechanism  is  due  to  the  metabolism
of ethanol  by  the  CYP2E1  isoform  of  the cytochrome
P450  producing  oxidative  stress  with  the generation  of
reactive  species  of  oxygen  and  the increase  of  lipid  per-
oxidation,  leading  to the alteration  of  the  compositions
of  phospholipids  of  the cellular  membrane.35,36 Membrane
lipid  peroxidation  results  in the loss  of  its  structure  and
integrity,  elevating  serum  levels  of  glutamyl-transpeptidase,
a  membrane-bonding  enzyme.  Ethanol  inhibits  glutathione
peroxidase;  it reduces  the activity  of  catalase  and  dismutase
superoxide.16
The  decrease  in the  activity  of  antioxidant  enzymes,  dis-
mutase  superoxide  and  peroxidase  glutathione  is  believed  to
come  as  a result  of  the  harmful  effects  of  free  radicals  pro-
duced  after  exposure  to  ethanol,  or  alternatively,  they  could
be  a  direct  effect  of  acetaldehyde,  a  product  of  ethanol
oxidation.
D-Galactosamine
This  hepatotoxin  generates  a  similar  damage  to  viral hepati-
tis  regarding  morphologic  and  functional  characteristics.  A
single  dose  can  cause  hepatocellular  necrosis  and  fatty  liver.
It  induces  the exhaustion  of the uracil  nucleotide,  result-
ing  in  the inhibition  of  RNA synthesis  and  consequently
of  proteins.37 The  toxicity  mechanism  causes  loss  of  the
activity  of  ion pumps  and  an increase  in  cellular  mem-
brane  permeability,  leading  to  enzyme  liberation  and  an
increase  in intracellular  Ca2+ concentration,  which  is  con-
sidered  responsible  for  cellular  death.16,36,38
Tert-Butyl  hydroperoxide  (t-BuOOH)
Metabolized  to  free  radicals  by  cytochrome  P450  in
hepatocytes  generating  lipid  peroxidation,  a  decrease  of
glutathione,  it reduces  the potential  of  the  mitochondrial
membrane  and cellular  damage;  generated  damage  is  simi-
lar  to  oxidative  stress,  which  occurs  in cells  and  tissues.36,39
Alternatively,  t-BuOOH  can  be converted  by  glutathione
peroxidase  into  tetr-butyl  alcohol  and glutathione  disulfide
(GSSG).  GSSG  is  converted  into  reduced  glutathione  (GSH)
by  the  GSSG  reductase,  generating  the oxidation  of  pyridine
nucleotides  (NAPD).  All  these events  alter  the homeostasis
of  Ca+2 which  is  considered  a critical  event  to  provide  open-
ings  in the  plasmatic  membrane,  and  thus  cellular  damage.40
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Thioacetamide
An  organic  compound  containing  sulfur,  originally  used as  a
fungicide  and currently  used for  the  treatment  of  leather,  in
labs  and  in  the textile  and paper  industries.29 It can induce
acute  and  chronic  hepatic  injuries  and acts  over the  synthe-
sis  of  protein,  DNA,  RNA  and over  -glutamyl  transpeptidase
(GGT)  activity.
Thioacetamide  is  bio-activated  by  the  CYP450  and/or  by
the  monooxigenase  system,  which  contains  flavin,  convert-
ing  the  compound  into  sulfine  (a  sulfoxide-type  compound)
and  later  into  sulfone-type  compounds.  Sulfine  is  responsible
for  generating  an increase  in the nucleus  volume,  nucle-
oli  enlargement,  an increase  in  intracellular  concentration
of  Ca+2,  generating  changes  in cellular  permeability  and
mitochondrial  dysfunction.  On  the  other  hand,  Sulfone-type
compounds  are  responsible  for the  liberation  of  nitric  oxide
synthase  and the  nuclear  factor  kappa  B (NF-B), protein
denaturalization  and  lipid  peroxidation.41--43
Liver  function  markers
A  decisive  step when  biological  activity  models  are per-
formed  is  the  analysis  of the activity  of the tested  analyte.
Depending  on  the selected  model  and  its  characteristics,
the  survival  rate  and  the damaged  biochemical  markers  can
be  determined.  Due to  the wide  variety  of  functions  per-
formed  by the  liver,  there  is  a  wide  range  of  markers  through
which  we  are  able  to  determine  the functionality  or  damage
generated  by  this organ  or  its cells.28 Although  there  is  no
biochemical  marker  specific to liver  damage,  the combina-
tion  of  several  of  these,  and  knowing  the correlation  they
have  with  the liver,  will  help  to  better  interpret  the results
of  the  hepatoprotective  models.  Markers  can  be  divided  into
tests  related  to  the  liver’s  excretory  function  (bilirubin),
tests  related  to  synthetic  function  (albumin  and prothrom-
bin  time)  and  tests  related  to  the integrity  of  hepatocytes
(transaminases,  alkaline  phosphatase,  GGT).
Transaminases  or  aminotransferases
Transaminases  or  aminotransferases  are enzymes  that  trans-
fer  a  group  of amino  from  an amino  acid to  an acid
-acetate.  This  process  is  an important  step  in the
metabolism  of  amino  acids.  The  aspartate  aminotrans-
ferase  (AST)  and the alanine  aminotransferase  (ALT)  are
widely  used  enzymes;  the increase  in  the liberation  of
these  transaminases  is  linked  to liver  dysfunction.  ALT cat-
alyzes  the  amino  group  transference  of the  L-alanine  to
-ketoglutarate  to  produce  pyruvate  and  L-glutamate;  it is
elevated  in  hepatic  and renal  diseases,  i.e.  hepatitis,  cir-
rhosis  and  mononucleosis.  AST  catalyzes  the transference
of  the  amino  group  of  the L-aspartate  to  -ketoglutarate  to
produce  oxaloacetate  and  L-glutamate;  the  heart,  liver  and
skeletal  muscle,  are  organs  rich  with  this  enzyme  and the
AST  liberation  is  proportional  to  the damage  generated.  In  a
myocardial  infarction  it  starts  to  increase  between  3 and  9 h
after  the  event,  reaching  its peak  on  the  second  day;  the
levels  normalize  between  the fourth  and the sixth  day.  In
hepatitis  cases,  observed  elevations  are between  7  and  12
times  its  normal concentrations,  with  increases  of up  to  100
times.28
Phosphatases
These  enzymes  belong  to  the  hydrolases  family  and are
known  for  their  ability  to  hydrolyze  a wide  variety  of
organophosphate  compounds  with  the  formation  of  phos-
phate  ions  and alcohols.  Clinically  relevant  phosphatases  are
acid  phosphatase  and alkaline  phosphatase.  Alkaline  phos-
phatase  (ALP)  is  produced  mainly  in the  liver  and bone;  when
there  are  no  osteogenic  diseases,  ALP  elevation  is  gener-
ally  linked  to  hepatobiliary  diseases.  It is  more  specific  in
obstructive  hepatic  processes.28,44
Transpeptidase  -glutamine  (GGT)
This  enzyme  is  bound  to the plasmatic  membrane,  which
catalyzes  the transference  of  the  -glutamine  group  of  a
peptide  to  itself  or  other  peptides.  It is  located  mainly  in
hepatocytes;  however  it can  also  be found  in the proximal
renal  tubules,  intestinal  epithelial  cells  and  the prostate.
High  GGTP  levels  usually  indicate  infection  in the liver,
pancreatic  and  biliary  zones.  The  specificity  of  the  test  is
relatively  low, but  since  it is  not  linked  to  bone  diseases,  it
is  used to  link  high  ALP  levels  to  liver  damage.44
Bilirubin
Bilirubin  is  the most important  metabolite  of the heme
group,  found in  hemoglobin,  myoglobin  and  cytochromes.
It is  highly  insoluble  in  water  in its  most  common  isomeric
form,  and  most of  it  is transported  by  albumin.  The  liver
is  responsible  for eliminating  bilirubin  by  turning  it  to  a
more  hydrosolube  compound,  thus  allowing  its  elimination
of  plasma  for  its  eventual  excretion.  It  is  the most  important
test  of  the hepatic  metabolic  function;  however,  it is  only
possible  to  determine  it  in  in vivo  models.44
Total proteins
The  liver  synthetizes  most  plasmatic  proteins,  and  in most
hepatic  diseases  the  levels  are reduced.  Albumin,  -1 antit-
rypsin,  ceruloplasmin,  and  -fetoprotein  are proteins  linked
to  acute  liver  damage.
Lactato  deshydrogenase  (LDH)
Lactato  deshydrogenase  is  an  enzyme  located  in the  cellular
cytoplasm.  It catalyzes  the  interconversion  of  the  lactate
and  pyruvate;  LDH  liberation  may  be interpreted  as  the
opening  of  the cellular  membrane  or  cellular  death.  This
enzyme  is  not specific  to  the  liver  and  it is widely  used
in  in vitro  models  because  it  is  expressed  in most  cellular
lines.45
AST,  ALT  and  ALP  are most  commonly  analyzed  in  all
hepatoprotective  models,  while  the  quantification  of  total
proteins  and  LDH  are  generally  used  as  parameters  of  in vitro
cytotoxicity.46
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Conclusions
Liver  diseases  are  a  major health  problem,  domestically
and  around  the world;  thus,  it  is  necessary  to  develop
new  molecules  which  help  counteract  or  prevent  them.  The
discovery  and  development  of  new drugs  begins  with  the
demonstration  of  the  pharmacological  effects,  to  later  con-
duct  safety  and  efficacy  studies  in human  beings.  In vitro
models  are  widely  used;  they  are fast,  cheap,  reproducible
techniques  and  require  a  lower  sample.  Nevertheless,  the
results  ought  to  be  reevaluated  by  other  models.  Ex vivo
models  are  an intermediate  point between  in vivo  and
in  vitro  models,  but  are  less  utilized.  Unlike  the other  two,
in  vivo  models  provide  a  wide  range  of  information.  They
are  widely  used to  verify  the activity  of  new compounds,
although  they  are  more  expensive  and go through  many
experimental  animals.  Hence,  they  are  generally  used  after
an  in  vitro  or  ex vivo  evaluation,  as  a  step  previous  to  clinical
trials.
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